3-(吡啶-2-氧基)-苯胺 | 86556-09-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(吡啶-2-氧基)-苯胺
• 中文别名: 3-(吡啶-2氧基)苯胺
• 英文名称: 3-(pyridin-2-yloxy)aniline
• 英文别名: 3-pyridin-2-yloxyaniline
• CAS: 86556-09-4
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD06825506
• 分子量: 186.213
• InChiKey: CLQMOPKXIBQKKG-UHFFFAOYSA-N

物化性质

• 熔点：
  76-78

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 储存条件：
  -20°C，干燥

反应信息

• 作为反应物：
  描述：

  3-(吡啶-2-氧基)-苯胺 生成 2-methyl-N-(3-pyridin-2-yloxyphenyl)benzamide
  参考文献：
  名称：

  DAUM, W.;PAUL, V.;SCHILLER, P.

  摘要：

  DOI：
• 作为产物：
  描述：

  间硝基苯酚 在 platinum(IV) oxide 氢气 、 caesium carbonate 、 potassium iodide 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 3-(吡啶-2-氧基)-苯胺
  参考文献：
  名称：

  N-[(Arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene d4 antagonists of novel structure

  摘要：

  Two series of compounds, N-[(arylmethoxy)phenyl] sulfonamides and N-[(arylmethoxy)naphthyl] sulfonamides, were prepared as leukotriene D4 (LTD4) antagonists. In the phenyl series, N-[3-(2-quinolinylmethoxy)phenyl]-trifluoromethanesulfonamide (Wy-48,252, 16) was the most potent inhibitor of LTD4-induced bronchoconstriction in the guinea pig. With an intragastric ID50 of 0.1 mg/kg (2-h pretreatment), 16 was 300 times more potent than LY-171,883. Compound 16 also intragastrically inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ID50 of 0.6 mg/kg. In vitro against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and L-cysteine, 16 produced a pKB value of 7.7. In the rat PMN assay 16 inhibited both 5-lipoxygenase and cyclooxygenase (IC50's = 4.6 and 3.3 microM). In the naphthyl series, N-[7-(2-quinolinylmethoxy)-2-naphthyl]trifluoromethanesulfonamide (Wy-48,090, 47) in addition to potent LTD4 antagonist activity (on isolated guinea pig trachea 47 had a pKB value of 7.04) also had antiinflammatory activity (63% inhibition at 50 mg/kg in the rat carrageenan paw edema assay and 34% inhibition of TPA-induced inflammation at 1 mg/ear in the mouse ear edema model). Perhaps the antiinflammatory activity of 47 was due to its additional activity of inhibiting both 5-lipoxygenase and cyclooxygenase enzymes (IC50's = 0.23 and 11.9 microM, respectively, in rat PMN).

  DOI：

  10.1021/jm00126a006

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
  申请人：TES PHARMA S R L

  公开号：WO2021170658A1

  公开（公告）日：2021-09-02

  The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

  本公开涉及能够调节NR2F6活性的化合物。本公开的化合物可用于预防及/或治疗与调节NR2F6活性相关疾病和障碍的方法。
• [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISO-INDOLINONE
  申请人：MONTE ROSA THERAPEUTICS

  公开号：WO2021069705A1

  公开（公告）日：2021-04-15

  Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.

  本公开涉及一种化合物或药用可接受盐或其立体异构体，其化学式为I，其中X1为直链或支链的C1-6烷基，C3-6环烷基，-C1-6烷基C3-6环烷基，C6-10芳基，5-10成员杂芳基，C1-6烷基C6-10芳基，C1-6烷基5-10成员杂芳基，其中X1未取代或取代为一个或多个卤素，直链或支链的C1-6烷基，直链或支链的C1-6杂烷基，CF3，CHF2，-O-CHF2，-O-(CH2)2-OMe，OCF3，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-OC(O)-C1-4烷基氨基，-C(O)O-C1-6烷基，-COOH，-CHO，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-6烷氧基或C1-6烷基羟基；X2为氢，C6-10芳基，5-10成员杂芳基，-O-(5-10成员杂芳基)，4-8成员杂环烷基，C1-4烷基4-8成员杂环烷基，-O-(4-8成员杂环烷基)，-O-C1-4烷基-(4-8成员杂环烷基)，-OC(O)-C1-4烷基-4-8成员杂环烷基或C6芳氧基，其中X2未取代或取代为一个或多个直链或支链的C1-6烷基，NH2，NMe2或5-6成员杂环烷基；n为0、1或2。
• [EN] ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'ISOINDOLINE UTILISABLES DANS LE CADRE DU TRAITEMENT DU CANCER
  申请人：CELGENE CORP

  公开号：WO2010053732A1

  公开（公告）日：2010-05-14

  Provided herein are isoindoline compounds such as those of formula (I), pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases. Formula (I)

  本文提供了诸如式(I)所示的异吲哚类化合物，包括含有一种或多种此类化合物的药物组合物，以及它们用于治疗、预防或管理各种疾病的方法。Formula (I)
• 2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist
  作者：Dehua Huang、Steve F. Poon、Deborah F. Chapman、Janice Chung、Merryl Cramer、Thomas S. Reger、Jeffrey R. Roppe、Lida Tehrani、Nicholas D.P. Cosford、Nicholas D. Smith

  DOI：10.1016/j.bmcl.2004.09.012

  日期：2004.11

  on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery of 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl)pyridine (10)-a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability.

  对3-（5-吡啶-2-基-2H-四唑-2-基）苄腈2的构效关系的研究导致了2-（2- [3-（吡啶-3-基氧基）苯基]-的发现。 2H-四唑-5-基）吡啶（10）-一种高效且选择性的mGlu5受体拮抗剂，在大鼠和跨物种口服生物利用度中具有良好的脑部渗透性和体内受体占有率。
• Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents
  作者：Jessica L. Bell、Andrew J. Haak、Susan M. Wade、Paul D. Kirchhoff、Richard R. Neubig、Scott D. Larsen

  DOI：10.1016/j.bmcl.2013.04.080

  日期：2013.7

  CCG-1423 (1) is a novel inhibitor of Rho/MKL1/SRF-mediated gene transcription that inhibits invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. We recently reported the design and synthesis of conformationally restricted analogs (e.g., 2) with improved selectivity for inhibiting invasion versus acute cytotoxicity. In this study we conducted a survey of aromatic substitution with

  CCG-1423 ( 1 ) 是一种新型的 Rho/MKL1/SRF 介导的基因转录抑制剂，可抑制基质胶转移模型中 PC-3 前列腺癌细胞的侵袭。我们最近报道了构象限制类似物（例如，2）的设计和合成，其具有提高的选择性以抑制侵袭与急性细胞毒性。在这项研究中，我们对芳香族取代进行了调查，目的是改善物理化学参数（例如，C  log  P，MW）以用于未来的体内功效研究。鉴定出两种新化合物可进一步减弱细胞毒性，并且在划痕试验中抑制 PC-3 细胞迁移的效力是2 的四倍。其中之一（8a, CCG-203971, IC 50  = 4.2 μM) 在小鼠中以 100 mg/kg/天 ip 耐受 5 天，并且能够达到超过迁移 IC 50长达 3 小时的血浆水平。